Prelude Corporation

Feb 12, 2025

Hannah Storm, Award-Winning Broadcaster and DCIS Patient Advocate, Partners with PreludeDx to Share How the DCISionRT Test Gave Her Confidence in Her Treatment Decision

Mar 06, 2020

PreludeDx Announces New Response Type Biosignature Data at the 37th Annual Miami Breast Cancer Conference

Feb 12, 2020

PreludeDx Appoints Edwin C. Hendrick Chief Commercial Officer

Dec 05, 2019

PreludeDx Announces David J. Dabbs, MD as Chief of Pathology and Director of BREAST SOS (Second Opinion Service)

Jun 18, 2019

PreludeDx Presents New Research in Luminal Stage 1 Breast Cancer Patients at the 2019 American Society of Clinical Oncology Annual Meeting

May 22, 2019

PreludeDx Receives New York State CLEP Approval for the DCISionRT® DCIS Test

May 08, 2019

Interim Analysis of DCISionRT PREDICT Study Shows Impact on DCIS Patients

May 01, 2019

PreludeDx to Present Results from PREDICT Study at ASBrS Annual Meeting

Dec 06, 2018

PreludeDx Presents Promising Research in Stage 1 Breast Cancer Patients at the 2018 San Antonio Breast Cancer Symposium

Aug 02, 2018

Journal of Clinical Cancer Research Publication Demonstrates that DCISionRT® Provides Prognostic and Predictive Power for Assessing a Patient's DCIS Risk

Apr 25, 2018

PreludeDx Announces DCISionRT(TM) PREDICT Registry Study

Dec 13, 2017

PreludeDx Unveils Predictive Assay in DCISionRT Breast DCIS Test at SABCS

Nov 30, 2017

PreludeDx Will Present DCISionRT(TM) Results from SweDCIS Randomized Trial at SABCS